Two of the four investigational COVID-19 vaccine candidates being developed by Pfizer Inc. and BioNTech have gained fast track designation from the US Food and Drug Administration.
The two candidates using the mRNA-based vaccine platform are BNT162b1 and BNT162b2 and are the most advanced in the partners’...






